BioPharmSignal logoBioPharmSignal

Biotech News

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

Charles River (CRL)Charles RiverEarnings

– Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance –

Related news

CRLCharles River2026-01-21 21:30 EST

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

CRLCharles River2026-07-15 12:00 EST

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

View all latest news

Charles River

Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and...

Recent company news

CRLCharles River2026-08-20 12:00 EST

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

CRLCharles River2026-08-05 11:00 EST

Charles River Laboratories Announces Second-Quarter 2026 Results

CRLCharles River2026-07-15 12:00 EST

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

CRLCharles River2026-07-13 12:00 EST

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

CRLCharles River2026-06-18 12:00 EST

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

Stock data

Close
295.19 USD
Market cap
8.42B USD
Exchange
NYSE
Sector
Biopharma
Location
United States